Hydroxyapatite Inhibitors
1 drugsAbout Hydroxyapatite
Hydroxyapatite is a naturally occurring mineral form of calcium phosphate that serves as a crucial structural component of bones and teeth. While not a traditional drug target, its unique properties have led to therapeutic applications.
Hydroxyapatite's ability to selectively bind therapeutic agents makes it a target for delivering localized therapies. Currently, there is no genetic evidence directly linking hydroxyapatite to specific diseases.
Hydroxyapatite is targeted by one FDA-approved drug, Xofigo, a small molecule developed by Bayer for oncology indications. Xofigo was first approved in 2013.
Top Hydroxyapatite Drugs
Bayer is the only company with an approved drug targeting hydroxyapatite.
Low competition suggests high barriers to entry or limited market potential.
Hydroxyapatite Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Hydroxyapatite, using small molecule modality.
The lack of diverse modalities represents a whitespace opportunity for novel approaches.
Hydroxyapatite Clinical Trials 21 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Hydroxyapatite. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 9 | 6 | 3 | 0 | 67% |
| Phase 2 | 8 | 7 | 1 | 0 | 88% |
| Phase 3 | 3 | 3 | 0 | 0 | 100% |
| Phase 4 | 1 | 0 | 0 | 1 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Hydroxyapatite Drug Approval Timeline (2013 - 2013)
The first and only drug targeting hydroxyapatite was approved in 2013.
A single approval over a decade indicates a saturated market or limited therapeutic potential.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 4 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Hydroxyapatite. A trial counts if an approved drug acting on Hydroxyapatite is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.